Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02858232 | MASCT-I Treatment for Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 46 | The First People's Hospital of LianyungangOTHER | 0 | Aug 11, 2016 | clinicaltrials |
| NCT02627430 | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 26, 2016 |
| clinicaltrials |
| NCT02063230 | To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 1 | Jul 21, 2016 | clinicaltrials |
| NCT01325558 | A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 30 | Altor BioScienceINDUSTRY | 1 | Jul 15, 2016 | clinicaltrials |
| NCT01017640 | Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Jul 11, 2016 | clinicaltrials |
| NCT00416637 | Bevacizumab in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 27 | Herbert Hurwitz, MDOTHER | 0 | Jul 7, 2016 | clinicaltrials |
| NCT00026195 | Irinotecan in Treating Aging Patients With Solid Tumors | completed | Phase 1 | 140 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT01090960 | A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors | completed | Phase 1 | 52 | Genentech, Inc.INDUSTRY | 1 | Jul 4, 2016 | clinicaltrials |
| NCT01532011 | Erlotinib in Combination With Pralatrexate in Advanced Malignancies | completed | Phase 1 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 4, 2016 | clinicaltrials |
| NCT00002994 | Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors | completed | Phase 1 | 355 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 28, 2016 | clinicaltrials |
| NCT01284192 | Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma) | completed | Phase 1 | 46 | Astellas Pharma IncINDUSTRY | 1 | Jun 28, 2016 | clinicaltrials |
| NCT00049023 | Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors | completed | Phase 1 | 27 | O'Dorisio, M SOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT01431547 | Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1) | completed | Phase 1 | 21 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 17, 2016 | clinicaltrials |
| NCT02122809 | Phase I Study of Chiauranib in Patients With Advanced Solid Tumors | completed | Phase 1 | 18 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jun 17, 2016 | clinicaltrials |
| NCT02076230 | A Phase 1 TH-302 Mass Balance Trial | completed | Phase 1 | 10 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Jun 10, 2016 | clinicaltrials |
| NCT00036946 | VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | — | Regeneron PharmaceuticalsINDUSTRY | 1 | Jun 3, 2016 | clinicaltrials |
| NCT00045266 | VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | — | Regeneron PharmaceuticalsINDUSTRY | 1 | Jun 3, 2016 | clinicaltrials |
| NCT01912222 | Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction | completed | Phase 1 | 48 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 2, 2016 | clinicaltrials |
| NCT02020226 | A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 40 | Threshold PharmaceuticalsINDUSTRY | 1 | Jun 2, 2016 | clinicaltrials |
| NCT00933777 | SORAVE - Sorafenib and Everolimus in Solid Tumors(SORAVE) | completed | Phase 1 | 36 | University of CologneOTHER | 1 | May 25, 2016 | clinicaltrials |
| NCT01349296 | BIBF 1120 and RAD001 in Solid Tumors - Phase I(BARIS) | completed | Phase 1 | 18 | University of CologneOTHER | 1 | May 20, 2016 | clinicaltrials |
| NCT00938457 | Stereotactic Radiation Therapy in Treating Patients With Liver Metastases | terminated | Phase 1 / Phase 2 | 3 | Mayo ClinicOTHER | 1 | May 19, 2016 | clinicaltrials |
| NCT00658658 | Panitumumab in Children With Solid Tumors | completed | Phase 1 | 31 | AmgenINDUSTRY | 1 | May 18, 2016 | clinicaltrials |
| NCT01418677 | An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function | completed | Phase 1 | 19 | Eisai Inc.INDUSTRY | 1 | May 17, 2016 | clinicaltrials |
| NCT02215850 | Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours | completed | Phase 1 | 24 | Welichem Biotech Inc.INDUSTRY | 1 | May 17, 2016 | clinicaltrials |
| NCT00512460 | RTA 744 Injection in Patients With Leptomeningeal Disease | terminated | Phase 1 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | May 16, 2016 | clinicaltrials |
| NCT01327313 | A Study of EMD525797 in Solid Tumor Patients in Japan | completed | Phase 1 | 27 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | May 13, 2016 | clinicaltrials |
| NCT01353781 | Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies | completed | Phase 1 | 39 | AstraZenecaINDUSTRY | 1 | Apr 26, 2016 | clinicaltrials |
| NCT01391533 | Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors(SARMET) | completed | Phase 1 | 72 | SanofiINDUSTRY | 4 | Apr 13, 2016 | clinicaltrials |
| NCT01711034 | A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer | completed | Phase 1 | 145 | Otsuka Pharmaceutical Development & Commercialization, Inc.INDUSTRY | 1 | Apr 5, 2016 | clinicaltrials |
| NCT01357330 | Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 18 | SanofiINDUSTRY | 1 | Apr 1, 2016 | clinicaltrials |
| NCT01930292 | Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies | terminated | Phase 1 | 31 | Debiopharm International SAINDUSTRY | 1 | Mar 24, 2016 | clinicaltrials |
| NCT01276496 | Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery | completed | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2016 | clinicaltrials |
| NCT00632424 | Phase 1 Trial of Oral Ixabepilone | terminated | Phase 1 | 23 | R-PharmINDUSTRY | 1 | Mar 10, 2016 | clinicaltrials |
| NCT01683149 | Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies | completed | Phase 1 | 13 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 4, 2016 | clinicaltrials |
| NCT00303732 | Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors(PTK/RAD) | completed | Phase 1 | 37 | Daniel George, MDOTHER | 1 | Mar 3, 2016 | clinicaltrials |
| NCT01664000 | A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors | completed | Phase 1 | 48 | Cellceutix CorporationINDUSTRY | 1 | Feb 24, 2016 | clinicaltrials |
| NCT00664586 | A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors | terminated | Phase 1 | 21 | Erimos PharmaceuticalsINDUSTRY | 1 | Feb 23, 2016 | clinicaltrials |
| NCT01450384 | Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 37 | Virginia Commonwealth UniversityOTHER | 1 | Feb 23, 2016 | clinicaltrials |
| NCT00554268 | Trial of PBI-05204 in Advanced Cancer Patients | completed | Phase 1 | 58 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 19, 2016 | clinicaltrials |
| NCT01844661 | Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumors. | completed | Phase 1 / Phase 2 | 20 | Hospital Infantil Universitario Niño Jesús, Madrid, SpainOTHER | 1 | Feb 19, 2016 | clinicaltrials |
| NCT00714181 | Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors | completed | Phase 1 | 38 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 18, 2016 | clinicaltrials |
| NCT01497626 | Lapatinib and Bortezomib in Patients With Advanced Malignancies | terminated | Phase 1 | 15 | Georgetown UniversityOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT01929486 | Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer. | unknown | Phase 1 | 58 | Aichi Medical UniversityOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT02537561 | Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Feb 11, 2016 | clinicaltrials |
| NCT01300533 | A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer | completed | Phase 1 | 58 | BIND TherapeuticsINDUSTRY | 1 | Feb 9, 2016 | clinicaltrials |
| NCT02444884 | MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors | completed | Phase 1 | 54 | Children's Oncology GroupNETWORK | 0 | Feb 9, 2016 | clinicaltrials |
| NCT00732836 | Hepatic Arterial Infusion (HAI) of Abraxane | completed | Phase 1 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 5, 2016 | clinicaltrials |
| NCT00920868 | XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib(XAD) | completed | Phase 1 | 22 | Herbert Hurwitz, MDOTHER | 1 | Feb 3, 2016 | clinicaltrials |
| NCT01799083 | Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas(CIK) | unknown | Phase 1 / Phase 2 | 100 | Han weidongOTHER | 1 | Jan 28, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Aug 11, 2016source: clinicaltrials